Trending...
- Massachusetts: Baker-Polito Administration Launches COVID-19 Vaccine CDC Pharmacy Partnership - Phase 1, Expands Vaccine Locations & Names Fenway Park as Mass Vaccination Site
- Boston: A message from Commissioner McCosh: Inauguration event accessibility
- The Atlas Group adds Corbin Raines to their list of professional property managers
BOSTON, Jan. 12, 2021 /PRNewswire/ -- Genuity Science, a genomics and data-sourcing, analytics and insights organization, today announced that it has been named a winner in the 2021 BIG Innovation Awards presented by the Business Intelligence Group. The BIG innovation Awards recognize those organizations and people who bring new ideas to life, and change the way we experience the world.
Genuity Science was honored for placing innovation front and center as it continues to change the drug development process by using a combination of population-scale genetics; a scalable, flexible software platform that addresses genomic big data challenges; and a new, groundbreaking approach to artificial intelligence (AI). In collaboration with Professor Michael Simons and his team at Yale University Medical School, the Genuity Science Advanced AI Research Laboratory used a new generative AI approach to discover, in mice studies, a novel pathobiological mechanism that causally underpins aortic aneurysm.
Genuity Science's AI technology sifted through a large amount of high-dimensional data without a starting hypothesis, allowing the teams to uncover novel causal connections at the single-cell level. Through a combination of single-cell biology and RNA sequencing, they discovered a group of abnormal cells that drive thoracic aortic aneurysm. By disrupting this process, they could reduce the incidence of the aneurysm altogether, giving researchers an unprecedented advantage in understanding that could better focus drug development efforts in humans.
More on Boston Chron
"We are honored to be recognized for our deep learning approach that helped, in part, discover the underlying cause of thoracic aortic aneurysms," said Tom Chittenden, PhD, DPhil, PStat, Chief Data Science Officer, Genuity Science. "This class of AI methods is changing the drug development process by providing the means to identify causal molecular underpinnings of diseases. This has the potential to bring down drug discovery costs. It can also speed up development timelines and improve treatment options for rare and common diseases."
"More than ever, the global society relies on innovation to help progress humanity and make our lives more productive, healthy, and comfortable," said Maria Jimenez, Chief Operating Officer of the Business Intelligence Group. "We are thrilled to be honoring Genuity Science as they are one of the organizations leading this charge and helping humanity progress."
The BIG Innovation Awards recognize organizations, products, and people who bring new ideas to life. Organizations from across the globe submitted their recent innovations for consideration in the BIG Innovation Awards. Nominations were then judged by a select group of business leaders and executives who volunteer their time and expertise to score submissions.
About Business Intelligence Group
The Business Intelligence Group was founded with the mission of recognizing true talent and superior performance in the business world. Unlike other industry award programs, these programs are judged by business executives having experience and knowledge. The organization's proprietary and unique scoring system selectively measures performance across multiple business domains and then rewards those companies whose achievements stand above those of their peers.
More on Boston Chron
About Genuity Science
Genuity Science is a data, analytics and insights organization headquartered in Boston, Massachusetts, USA, with offices in Dublin, Ireland and Reykjavik, Iceland. Genuity Science partners with global biopharma and life sciences companies to offer deep end-to-end drug target and biomarker discovery programs aimed at catalyzing precision health and improving the quality of life for patients around the world. Genuity's programs include population-scale, disease-specific data sourcing with detailed longitudinal clinical information, high-quality sequencing, a uniquely scalable genomic and clinical database architecture and tools for analyzing large datasets, and advanced artificial intelligence (AI). The company operates an advanced CAP-accredited laboratory in Dublin, Ireland, and is deeply committed to responsible and compliant data stewardship across its global offices. For more information, see www.genuitysci.com.
SOURCE Genuity Science
Genuity Science was honored for placing innovation front and center as it continues to change the drug development process by using a combination of population-scale genetics; a scalable, flexible software platform that addresses genomic big data challenges; and a new, groundbreaking approach to artificial intelligence (AI). In collaboration with Professor Michael Simons and his team at Yale University Medical School, the Genuity Science Advanced AI Research Laboratory used a new generative AI approach to discover, in mice studies, a novel pathobiological mechanism that causally underpins aortic aneurysm.
Genuity Science's AI technology sifted through a large amount of high-dimensional data without a starting hypothesis, allowing the teams to uncover novel causal connections at the single-cell level. Through a combination of single-cell biology and RNA sequencing, they discovered a group of abnormal cells that drive thoracic aortic aneurysm. By disrupting this process, they could reduce the incidence of the aneurysm altogether, giving researchers an unprecedented advantage in understanding that could better focus drug development efforts in humans.
More on Boston Chron
- Congressional Medal of Honor Society will host 2021 convention in Boston
- Boston: Update on the Ronan Park Well
- Avery Design Announces CXL™ 2.0 VIP
- Nova Biomedical FLEX2 Cell Culture Analyzer Adds Sample Retain Capability
- Kaizen Finance Launches Staking to Foster the Widespread Adoption of DeFi
"We are honored to be recognized for our deep learning approach that helped, in part, discover the underlying cause of thoracic aortic aneurysms," said Tom Chittenden, PhD, DPhil, PStat, Chief Data Science Officer, Genuity Science. "This class of AI methods is changing the drug development process by providing the means to identify causal molecular underpinnings of diseases. This has the potential to bring down drug discovery costs. It can also speed up development timelines and improve treatment options for rare and common diseases."
"More than ever, the global society relies on innovation to help progress humanity and make our lives more productive, healthy, and comfortable," said Maria Jimenez, Chief Operating Officer of the Business Intelligence Group. "We are thrilled to be honoring Genuity Science as they are one of the organizations leading this charge and helping humanity progress."
The BIG Innovation Awards recognize organizations, products, and people who bring new ideas to life. Organizations from across the globe submitted their recent innovations for consideration in the BIG Innovation Awards. Nominations were then judged by a select group of business leaders and executives who volunteer their time and expertise to score submissions.
About Business Intelligence Group
The Business Intelligence Group was founded with the mission of recognizing true talent and superior performance in the business world. Unlike other industry award programs, these programs are judged by business executives having experience and knowledge. The organization's proprietary and unique scoring system selectively measures performance across multiple business domains and then rewards those companies whose achievements stand above those of their peers.
More on Boston Chron
- Ismail Sirdah Describes the Best Practices for Holding Corporate Events
- MDAdvantage Appoints Pete Cammarano to Board of Directors
- CEO Coaching International Congratulates Client Orion Energy on Successful Capital Partnerships
- expEDIum Direct Pay®, seamless online payment added to iTech's expEDIum Medical Billing®
- Office Properties Income Trust Fourth Quarter 2020 Conference Call Scheduled for Friday, February 19th
About Genuity Science
Genuity Science is a data, analytics and insights organization headquartered in Boston, Massachusetts, USA, with offices in Dublin, Ireland and Reykjavik, Iceland. Genuity Science partners with global biopharma and life sciences companies to offer deep end-to-end drug target and biomarker discovery programs aimed at catalyzing precision health and improving the quality of life for patients around the world. Genuity's programs include population-scale, disease-specific data sourcing with detailed longitudinal clinical information, high-quality sequencing, a uniquely scalable genomic and clinical database architecture and tools for analyzing large datasets, and advanced artificial intelligence (AI). The company operates an advanced CAP-accredited laboratory in Dublin, Ireland, and is deeply committed to responsible and compliant data stewardship across its global offices. For more information, see www.genuitysci.com.
SOURCE Genuity Science
Filed Under: Business
0 Comments
Latest on Boston Chron
- Pro Golfer Kamaiu Johnson Joins Cambridge Mobile Telematics as Brand Ambassador
- Empirix Helps CEHE Confidently Migrate to Five9 Cloud-Based Contact Center Software USA - English USA - English
- Northway Biotech Opens New Biopharmaceutical Manufacturing Facility in Greater Boston Area
- Manulife Investment Management announces new managing director of institutional distribution, southeast region
- Boston: Meet some of this year's Opportunity Fund grantees
- City Streaming TV, a Streaming Television Inc Network Launches, bringing Community and Faith Leaders into local TV's, At No Cost
- Perini Management Services, Inc. Announces Two Federal Contracts Collectively Valued at $66.9 Million
- "GLORY of HISTORY" Hip-Hop Music Video Looks At Voter's Choice
- BoatDealers.ca Surges with Record Traffic in 2020
- CoVerified Announces Partnership with Mirimus for Nationwide K-12 Pooled Saliva COVID-19 Testing Program
- Reify Health Announces Global Expansion of StudyTeam to Over 2,700 Clinical Research Sites
- 'Aesthetic Institute of Massachusetts' Announces Rebranding to 'Aesthetic Mentor'
- OCC Adopts Final Rule Requiring Large Banks to Provide Fair Access to Banking Services
- New GCI Study On Gynecologic Cancers in Brazil Finds Most Patients Present With Advanced Disease
- The Antenna Company Announces Venture Debt Financing Agreement with Brabant Development Agency (BOM)
- Haemonetics To Acquire Cardiva Medical, Inc. To Expand Hospital Portfolio
- Cohere Capital Completes Strategic Growth Investment in CCS, a Leading Digital Brand and E-Commerce Retailer
- Syros Announces Pricing of $75.6 Million Public Offering of Common Stock
- Code18 Interactive Launches New Websites for Balmex and Balmex Adult
- LabMinds Successfully Receives Approval for Use in a GMP Certified Laboratory.